Partial Seizure – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Partial Seizure Market Outlook

Thelansis’s “Partial Seizure Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Partial Seizure treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Partial Seizure Overview

Partial seizures, often referred to as "focal seizures," primarily impact a specific brain region, with the temporal lobes being the most common location of occurrence. They can be categorized into two main types: simple partial seizures, which occur without a loss of consciousness, and complex partial seizures, which involve impaired consciousness. When a partial seizure extends to affect the entire brain, it is termed a "partial seizure with secondary generalization." Partial seizures are the most prevalent form of seizures among individuals with epilepsy. Notably, complex partial seizures are more frequent than simple partial seizures, though many complex partial seizures initially manifest as simple partial seizures. Seizures result from episodes of excessive and disorganized neuronal activity within the brain. Ordinarily, electrical signals are conveyed through an action potential with a net influx of positive ions, leading to neuron depolarization. Hyperexcitability is typically held in check by various inhibitory mechanisms involving negative ions like chloride ions and inhibitory neurotransmitters. Altered voltage-gated ion channels can disrupt this balance, leading to heightened excitatory transmission and reduced inhibitory signals, thereby causing hyperexcitability. Glutamate serves as the primary excitatory neurotransmitter in the brain, while GABA acts as the inhibitory counterpart. When excitation prevails over inhibition in neurons, hyperexcitability occurs. The convergence of an epileptic focus, hyperexcitability, and hyper-synchronization among neurons ultimately triggers seizures. There is no drug of choice for treating seizures. Commonly employed first-line medications for partial epilepsy encompass carbamazepine and lamotrigine. Secondary options may be considered if these medications fail to control seizures, including valproate, topiramate, oxcarbazepine, or gabapentin. Notably, lamotrigine is the preferred treatment for partial seizures associated with secondary generalization. Patients experiencing partial seizures face a greater risk of seizure recurrence than those with generalized seizures. However, recurrence rates appear similar between simple and complex partial seizures. Furthermore, simple partial seizures, which do not involve a loss of consciousness, carry a lower risk of seizure-related complications such as aspiration and exhibit a reduced overall morbidity and mortality rate compared to seizures that impair consciousness. Simple partial seizures can also result in falls and injuries.

• In the United States, partial seizures are estimated to be around 20 cases per 100,000 individuals aged 1-65. According to the CDC, approximately 3.4 million people in the United States are affected by epilepsy, including 3 million adults and 470,000 children.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: